Der Bioverteidigungsmarkt wird im Jahr 2027 voraussichtlich 8.350,74 Mio. US-Dollar erreichen, gegenüber 4.108,24 Mio. US-Dollar im Jahr 2019. Es wird geschätzt, dass der Markt von 2020 bis 2027 mit einer jährlichen Wachstumsrate von 9,4 % wächst.< /h3>
Biodefense bezieht sich auf Maßnahmen zur Wiederherstellung der Biosicherheit einer Gruppe von Organismen, die biologischen Bedrohungen oder Infektionskrankheiten ausgesetzt sind oder sein könnten. Es handelt sich um ein wirksames öffentliches Gesundheitssystem mit strenger Krankheitsüberwachung und schnellen Maßnahmen zur Bekämpfung biologischer Bedrohungen, zur Eindämmung der Ausbreitung von Krankheiten und zur Bereitstellung einer umfassenden medizinischen Versorgung. Das Wachstum des Marktes wird auf einige wichtige treibende Faktoren zurückgeführt, wie z. B. das Vorhandensein günstiger Regierungsinitiativen, die Zunahme natürlich vorkommender Ausbrüche und die zunehmende Bedrohung durch biologische Waffen und nuklear bewaffnete Interkontinentalraketen. Es wird jedoch erwartet, dass die geringe staatliche Finanzierung von Forschung und Entwicklung in Entwicklungs- und unterentwickelten Volkswirtschaften das Wachstum des Bioverteidigungsmarkts in den prognostizierten Jahren bremsen wird.
Lukrative regionale Bioverteidigungsmärkte
< /div>
Markteinblicke
Vorhandensein günstiger Regierungsinitiativen
Jedes Jahr gibt die Regierung viel Geld für die Forschung und Entwicklung von Impfstoffen aus, um auf etwaige bioterroristische Angriffe vorbereitet zu sein. Beispielsweise veröffentlichte die US-Regierung im Jahr 2018 die Nationale Bioverteidigungsstrategie und den Umsetzungsplan, die Nationale Sicherheitsstrategie, die Nationale Verteidigungsstrategie, die Nationale Strategie zur Terrorismusbekämpfung und die Nationale Strategie zur Bekämpfung von Massenvernichtungswaffen, die alle Biosicherheit und Bioverteidigung umfassen. Darüber hinaus bereitet die US-Regierung auch die globale Gesundheitssicherheitsstrategie vor und unterstützt die Entwicklung eines Rahmenwerks der globalen Gesundheitssicherheitsagenda für 2024, das die Prävention, Erkennung und Reaktion auf natürliche, zufällige und absichtliche biologische Bedrohungen umfasst.
Verbesserung von Influenza-Impfstoffen und Gesundheitssicherheit ist das Budget, das die Executive Order 13887 Modernisierung von Influenza-Impfstoffen in den Vereinigten Staaten zur Förderung der nationalen Sicherheit und der öffentlichen Gesundheit unterstützt. durch die Bereitstellung einer Aufstockung um 95 Millionen US-Dollar gegenüber dem im Jahr 2020 beschlossenen Betrag im gesamten Gesundheits- und Sozialwesen (HHS) für die Infrastruktur und Innovation bei der Herstellung von Influenza-Impfstoffen; fortgeschrittene Forschung und Entwicklung verbesserter Impfstoffe, Therapeutika und Diagnostika; internationale Pandemievorsorge; und eine landesweit verbesserte Durchimpfungsrate. Der Haushalt finanziert auch die Beschaffung von Bioabwehr- und Notfallvorsorgemaßnahmen des HHS über das BioShield-Programm und den Strategic National Stockpile. Darin sind 175 Millionen US-Dollar zur Unterstützung der globalen Gesundheitssicherheitsaktivitäten des CDC enthalten, eine Steigerung von 50 Millionen US-Dollar im Vergleich zum 2020 beschlossenen Betrag.
Während sich die Regierung an diesen aktuellen und zukünftigen politischen Aktivitäten beteiligt, muss sie die bestehende Biosicherheits- und Bioverteidigungspolitik verstehen , haben die im Bioverteidigungsmarkt tätigen Pharmaunternehmen erhebliche Expansionsmöglichkeiten und sind auf jeden Bioterrorismus vorbereitet. Beispielsweise hat der Antibiotika-Entwickler Spero Therapeutics von der Biomedical Advanced Research and Development Authority 15,7 Millionen US-Dollar an bundesstaatlichen Forschungsmitteln für seinen oralen Carbapenem-Klasse-Kandidaten SPR994 erhalten, um die Wirksamkeit des Medikaments gegen biologische Bedrohungen wie Anthrax, Pest und Melioidose zu bewerten. Darüber hinaus sieht die Biomedical Advanced Research and Development Authority Rückstellungen für bis zu zusätzliche 28,5 Millionen US-Dollar über einen Zeitraum von fünf Jahren vor und wird Speros außerdem die klinische Entwicklung von SPR994 bei komplizierten Harnwegsinfektionen unterstützen, die durch arzneimittelresistente Bakterien verursacht werden. Die Initiativen von Regierungen auf der ganzen Welt eröffnen den Unternehmen, die im Bioverteidigungssektor tätig sind, ein Fenster voller Möglichkeiten.
Produkteinblicke
Der Bioverteidigungsmarkt ist nach Produkten unterteilt in Milzbrand, Pocken, Botulismus, Strahlung/Atom und andere. Im Jahr 2019 hatte das Anthrax-Segment den größten Marktanteil am globalen Bioverteidigungsmarkt. Es wird erwartet, dass das Segment seine Dominanz im Prognosezeitraum aufgrund der zunehmenden Finanzierung durch die Regierungen anderer Länder für die Entwicklung und Bevorratung ausreichender Impfstoffe gegen Milzbrand vor allem durch eine Vielzahl von Initiativen wie BioShield Act und Biomedical Advanced Research and Development Authority (BARDA) beibehalten wird ) und das Joint Program Executive Office for Chemical & Biologische Verteidigung.
Globaler Markt für biologische Verteidigung, nach Produkten 2018 & 2027
Strategische Einblicke
Produkteinführungen und Zulassungsstrategien werden häufig von Unternehmen übernommen, um ihre Präsenz weltweit zu erweitern und der wachsenden Nachfrage gerecht zu werden. Diese Strategie wird am häufigsten von den Marktteilnehmern übernommen, um ihr Produktportfolio zu erweitern.
Die auf dem Bioverteidigungsmarkt tätigen Marktteilnehmer verfolgen die Strategie der Expansion, um den Kundenstamm auf der ganzen Welt zu vergrößern, was auch dies ermöglicht Spielern, ihren Markennamen weltweit zu behaupten. Beispielsweise hat Emergent BioSolutions Inc. im Januar 2017 die Genehmigung des deutschen Bundesministeriums für Gesundheit für die Vermarktung von BioThrax (Anthrax-Impfstoff adsorbiert) erhalten, der in Gebäude 55 in Deutschland hergestellt wird.
Globaler Bioverteidigungsmarkt nach Produkt
- Anthrax
- Kleinpocken
- Botulismus
- Strahlung/Nuklear
- Andere
Biodefense-Markt nach Geografie
- Nordamerika
- USA
- Kanada
- Mexiko
< /ul>
- Europa
- Frankreich
- Deutschland
- Italien
- Großbritannien
- Spanien
- Restliches Europa
- Asien-Pazifik
- China
- Indien
- Süden Korea
- Japan
- Australien
- Übriger Asien-Pazifik-Raum
- Naher Osten & Afrika
- Südafrika
- Saudi-Arabien
- VAE
- Übriger Naher Osten und Afrika
- Südamerika
- Brasilien
- Argentinien
- Übriges Südamerika
Unternehmensprofile
- Bavarian Nordic
- Alnylam Pharmaceuticals, Inc.
- SIGA Technologies
- Emergent BioSolutions Inc.
- Cleveland Bio Labs
- Dynavax Technologies
- Elusys Therapeutics, Inc.
- Soligenix
- Altimmune
- Pluristem Therapeutics
Biodefense-Markt nach Geografie
- Nordamerika
- USA
- Kanada
- Mexiko
< /ul> - Europa
- Frankreich
- Deutschland
- Italien
- Großbritannien
- Spanien
- Restliches Europa
- Asien-Pazifik
- China
- Indien
- Süden Korea
- Japan
- Australien
- Übriger Asien-Pazifik-Raum
- Naher Osten & Afrika
- Südafrika
- Saudi-Arabien
- VAE
- Übriger Naher Osten und Afrika
- Südamerika
- Brasilien
- Argentinien
- Übriges Südamerika
Unternehmensprofile
- Bavarian Nordic
- Alnylam Pharmaceuticals, Inc.
- SIGA Technologies
- Emergent BioSolutions Inc.
- Cleveland Bio Labs
- Dynavax Technologies
- Elusys Therapeutics, Inc.
- Soligenix
- Altimmune
- Pluristem Therapeutics
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Biodefense is referred to the measures taken to restore biosecurity of a group of organism that are, or may be, subject to biological threats or infectious diseases. It is an effective public health care system with strong disease surveillance and rapid actions designed to counter biological threats, to limit the spread of disease and provide surge medical care.
Driving factors such as presence of favorable government initiatives increase in the number of naturally occurring outbreaks, increasing threat of biological weapons and nuclear armed ICBM. Additionally, the future trend such as predictive analytics to reshape biodefense market is likely to increase the growth in the forecast period.
Global biodefense market is segmented by region into North America, Europe, Asia Pacific, Middle East & Africa and South & Central America. In North America, the U.S. is the largest market for biodefense. Biological threats occurring to humans, animals and environment are among the most serious issues faced by the US and its national community. As the biological threat continues to increase, the US is focused towards strengthening its capabilities and considering preparation for bio threats and bioterrorism as one of the critical aspects of national security. The federal government in the US coordinates programs, and sets up budgets so as to prevent, respond and take actions against biological disasters.
The List of Companies - Biodefense Market
- Bavarian Nordic
- Alnylam Pharmaceuticals, Inc.
- SIGA Technologies
- Emergent BioSolutions Inc.
- Cleveland Bio Labs
- Dynavax Technologies
- Elusys Therapeutics, Inc.
- Soligenix
- Altimmune
- Pluristem Therapeutics
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Mar 2020
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Mar 2020
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Mar 2020
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Mar 2020
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Mar 2020
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Mar 2020
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Mar 2020
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)